FAQ: Clene Inc. Q2 2025 Results and CNM-Au8 NDA Submission Plans

What is Clene Inc. planning to submit to the FDA and for which condition?

Clene Inc. plans to submit a New Drug Application (NDA) for its lead candidate CNM-Au8® in amyotrophic lateral sclerosis (ALS) by year-end 2025, as part of their focus on treating neurodegenerative diseases.

When are the FDA meetings scheduled and what will they address?

FDA meetings are scheduled in Q3 2025 and will address ALS survival benefit data and multiple sclerosis (MS) development plans, helping align on regulatory pathways for CNM-Au8.

What is CNM-Au8 and how does it work?

CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by improving energy metabolism, targeting mitochondrial health to treat neurodegenerative diseases like ALS and MS.

What financial position does Clene Inc. report as of Q2 2025?

As of June 30, 2025, Clene reported $7.3 million in cash and cash equivalents, with recent financing extending the company’s cash runway into Q1 2026, providing financial stability for ongoing development.

When is neurofilament light biomarker data analysis expected?

Neurofilament light biomarker data analysis from the NIH-sponsored EAP program is expected in early Q4 2025, following a recent Type C meeting with the FDA to align on statistical methodology.

What neurodegenerative diseases does Clene focus on treating?

Clene focuses on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

Where can investors find the latest news and updates about Clene Inc.?

The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN, as provided in the investor note section of the content.

What is the significance of the NDA submission timeline for CNM-Au8?

The planned NDA submission by year-end 2025 represents a critical regulatory milestone that could lead to approval of CNM-Au8 for ALS treatment, addressing a significant unmet medical need in neurodegenerative disease.